SPARE trial - Crohn's disease

 RCT looking at withdrawal of infliximab or immunomodulator, in patients on combination therapy and in remission for atleast 6 months

- 211 patients randomized in 7 countries (Australia / Nordic countries, UK, France) to either continuing both, stopping infliximab or stopping immunomodulator 

- Patients with fistulising disease, or severe reaction to infliximab were excluded.



Risk of relapse at 2 years:

Combination therapy: 14%

Ifx stopped = 36%

immunomodulator stopped = 10%


Nearly all patients who relapsed on Ifx withdrawal were promptly re-captured by starting Ifx


Stopping Ifx in patients with CD on combination therapy results in an excess 21% increase in risk of relapse. 

No increase risk of relapse in stopping immunomodulator after stable remission has been achieved.

Comments

Post a Comment

Popular posts from this blog

Hep B / HCC screening - ReachB

Image
 https://www.youtube.com/watch?v=3cP2kvPq7iQ m.c form of acquiring Hep B in Asia - Vertically m.c form of acquiring Hep B in western coutnries: Parenterally (sexual / needles etc) Neonates have immature immune system, so they cant 'fight-off' vertically acquired virus. Over 90% of babies infected with Hep B, go on to have chronic Hep B infection 95% of adults if they acquire Hep B - fight it off! HBV is a DNA virus - replicates efficiently. But is error-prone. Plagued with mutants.  e-antigen negative mutant - tend to be in older patients, tend to be more aggressive. 30-50% of HCC in HBV occurs in absence of cirrhosis. Reveal study - 15 year follow-up study of untreated patients with HEp B. The only factor that was relevant in predicting risk of HCC was viral load at base-line! Viral load more than 10*4 (2000 IU/ml) was predictive of risk of HCC or Cirrhosis (similar graph for Cirrhosis as for HCC) Immune Tolerant Phase: typically after vertical infection. DNA remains very hig...
Read more